3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3h)-one and Atherosclerosis

3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3h)-one has been researched along with Atherosclerosis* in 2 studies

Other Studies

2 other study(ies) available for 3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3h)-one and Atherosclerosis

ArticleYear
Heterogeneous nuclear ribonucleoprotein E1 regulates protein disulphide isomerase translation in oxidized low-density lipoprotein-activated endothelial cells.
    Acta physiologica (Oxford, England), 2015, Volume: 213, Issue:3

    Endothelium-derived protein disulphide isomerase (PDI) is required for thrombus formation in vivo. But, how to control PDI overproduction in oxidized low-density lipoprotein (oxLDL)-activated vascular endothelial cells (VECs) is not well understood. In this study, we try to answer this question using our newly identified activator of mTOC1 3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2 (3H)-one (3BDO) that has been shown to protect VECs.. First, we performed a proteomics analysis on the oxLDL-activated vascular VECs in the presence or absence of 3BDO. Next, we constructed the heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) mutants at Ser43 and used the RNA-ChIP technique to investigate the relationship between hnRNP E1 and PDI production. Furthermore, we examined the effect of 3BDO on oxLDL-altered phosphorylation of Akt1 and Akt2. Finally, we studied the effect of 3BDO on oxLDL-altered PDI protein level in apolipoprotein E(-/-) mice with advanced atherosclerosis.. In VECs, oxLDL-increased PDI protein level, induced hnRNP E1 phosphorylation at Ser43, suppressed the binding of hnRNP E1 to PDI 5'UTR and induced the phosphorylation of Akt2 but not Akt1. All of these processes were blocked by 3BDO. Importantly, Ser43 mutant of hnRNP E1 inhibited the increase of PDI protein level and the decrease of the binding of hnRNP E1 and PDI 5'UTR induced by oxLDL. Furthermore, 3BDO suppressed oxLDL-induced PDI protein increase in the serum and plaque endothelium of apolipoprotein E(-/-) mice.. hnRNP E1 is a new regulator of PDI translation in oxLDL-activated VECs, and 3BDO is a powerful agent for controlling PDI overproduction.

    Topics: 4-Butyrolactone; 5' Untranslated Regions; Animals; Apolipoproteins E; Atherosclerosis; Binding Sites; Cells, Cultured; Disease Models, Animal; DNA-Binding Proteins; Heterogeneous-Nuclear Ribonucleoproteins; Human Umbilical Vein Endothelial Cells; Humans; Lipoproteins, LDL; Mice, Inbred C57BL; Mice, Knockout; Mutation; Phosphorylation; Protein Disulfide-Isomerases; Proteomics; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; Transfection

2015
An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E⁻/⁻ mice.
    Scientific reports, 2014, Jul-01, Volume: 4

    Oxidized low-density lipoprotein (oxLDL) inhibits mammalian target of rapamycin (mTOR) and induces autophagy and apoptosis in vascular endothelial cells (VECs) that play very critical roles for the cardiovascular homostasis. We recently defined 3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3H)-one (3BDO) as a new activator of mTOR. Therefore, we hypothesized that 3BDO had a protective role in VECs and thus stabilized atherosclerotic lesions in apolipoprotein E(-/-) (apoE(-/-)) mice. Our results showed that oxLDL inhibited the activity of mTOR and increased the protein level of autophagy-related 13 (ATG13) and its dephosphorylation, thus inducing autophagy in human umbilical vein endothelial cells (HUVECs). All of these effects were strongly inhibited by 3BDO. In vivo experiments confirmed that 3BDO activated mTOR and decreased the protein level of ATG13 in the plaque endothelium of apoE(-/-) mice. Importantly, 3BDO did not affect the activity of mTOR and autophagy in macrophage cell line RAW246.7 and vascular smooth muscle cells of apoE(-/-) mice, but suppressed plaque endothelial cell death and restricted atherosclerosis development in the mice. 3BDO protected VECs by activating mTOR and thus stabilized atherosclerotic lesions in apoE(-/-) mice.

    Topics: 4-Butyrolactone; Animals; Apolipoproteins E; Atherosclerosis; Autophagy; Dose-Response Relationship, Drug; Endothelial Cells; Lipoproteins, LDL; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; TOR Serine-Threonine Kinases; Treatment Outcome

2014